Key Drivers
- Strong liquidity
- Weak profitability
- High valuation
AIAI Summary
Castle Biosciences has shifted into a growth-at-the-cost-of-profitability profile: high‑margin core diagnostics and strong test-volume/cash generation fund aggressive commercial and evidence investments, but rising SG&A/R&D and stretched valuation mean GAAP losses and margin pressure are deliberate near‑term tradeoffs. Monitor quarterly adjusted EBITDA expansion, lab utilization, and concrete payer/LCD wins for DecisionDx‑SCC or AdvanceAD‑Tx (or a sustained break above $27–29); absent those, execution or reimbursement setbacks could trigger sharp downside.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •Weak profitability
- •High valuation
CSTL combines strong liquidity, low leverage and positive EBITDA/FCF with persistent operating losses driven by very high SG&A/R&D and D&A, while trading at a stretched EV/EBITDA implying limited downside protection.
Price Behavior
Key Price Behavior Insights:
- •Downtrend persistence
- •Support cluster
- •Resistance friction
CSTL is in a clear short-term downtrend (prices ~14% below month-ago levels and ~9% below the last month average), trading near immediate support $25.00–$25.32 with resistance at ~$27.5 and $27–$29, so a break below $25 would expose the low‑20s while rallies will likely stall until those resistance zones are cleared.
Sharp pullback from $40–$43 in
Sentiment & News
Key News Insights:
- •Revenue beat
- •Narrower loss
- •Strong clinical data
Castle Biosciences beat full-year revenue and narrowed its Q4 loss while advancing DecisionDx‑Melanoma i31‑SLNB data and opening a new HQ, though shares fell after the results.
Positive revenue and clinical progress support long-term growth potential, but the near-term stock reaction suggests investors wanted stronger guidance or market response
Similar Companies in Healthcare
Other companies in the same sector with AI ratings